ArticleEuropean journal of human genetics : EJHG2026
Variant-specific functional effects of CTNNA1 in a humanized Drosophila model.
Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Germline variants in CTNNA1, encoding αE-catenin, have been implicated in hereditary diffuse gastric cancer (HDGC) and macular dystrophy patterned-2 (MDPT2). However, the functional mechanisms associated specifically with each molecular variant type underlying these distinct clinical outcomes remain poorly understood. Here, we established a humanized Drosophila melanogaster model conditionally targeting two distinct Drosophila tissues: the eye and the wing. We assessed the functional impact of eight CTNNA1 variants identified in 50 carrier families. We used tissue-specific RNAi and CRISPR/Cas9 to deplete endogenous Drosophila α-catenin (Dα-cat) and expressed either human wild-type (WT) or mutant αE-catenin (Hα-cat). We demonstrate that WT Hα-cat rescued Dα-cat loss, supporting conserved functionality across species. Hα-cat truncating variants failed to rescue epithelial architecture or viability and were associated with increased apoptosis, although one nonsense variant located in the CTNNA1 last exon exhibited milder phenotypes. Interestingly, while most missense variants behaved similarly to WT, p. Asn853Ser, in CTNNA1 last exon, exhibited partial functional loss and did not fully rescue apoptosis caused by Dcat expression loss. These results highlight variant-type and tissue-type specificities. This work provides a humanized Drosophila model for the CTNNA1 gene, which reveals variant-type and locus-specific impacts of CTNNA1 alterations, occurring either in HDGC or MDPT2 families. Our study highlights the value of in vivo functional modeling for clinical variant interpretation and supports improved classification and management strategies for CTNNA1 variant carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.